Compugen (CGEN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compugen Ltd. announced a solid Q2 2024 performance with FDA clearance for COM503 triggering a $30 million milestone payment from Gilead and a strong cash position expected to fund operations until 2027. The company is also preparing to present ovarian cancer study data and anticipates future revenue from AstraZeneca’s development of rilvegostomig, with a potential market of over $5 billion. Compugen’s financial results showed a significant reduction in net loss compared to the previous year and a healthy cash reserve.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package